Concepts (200)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mastectomy, Segmental | 38 | 2017 | 955 | 3.580 |
Why?
|
| Breast Neoplasms | 69 | 2017 | 20774 | 2.460 |
Why?
|
| Radiotherapy, Adjuvant | 23 | 2016 | 1769 | 1.520 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 13 | 2016 | 947 | 1.470 |
Why?
|
| Neoplasm Recurrence, Local | 29 | 2017 | 9185 | 1.300 |
Why?
|
| Radiation Oncology | 10 | 2016 | 554 | 1.240 |
Why?
|
| Mastectomy | 9 | 2017 | 1789 | 1.050 |
Why?
|
| Lymphatic Metastasis | 10 | 2016 | 2906 | 0.740 |
Why?
|
| Patient Selection | 5 | 2016 | 4214 | 0.710 |
Why?
|
| Brachytherapy | 4 | 2016 | 1246 | 0.680 |
Why?
|
| Neoplasm, Residual | 4 | 2017 | 974 | 0.570 |
Why?
|
| Lymph Nodes | 6 | 2016 | 3465 | 0.520 |
Why?
|
| Neoplasm Staging | 18 | 2016 | 11001 | 0.460 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 2014 | 94 | 0.460 |
Why?
|
| Consensus | 4 | 2016 | 2935 | 0.440 |
Why?
|
| Carcinoma, Ductal, Breast | 4 | 2016 | 1101 | 0.420 |
Why?
|
| Receptors, Progesterone | 6 | 2012 | 1097 | 0.420 |
Why?
|
| Radiotherapy, Intensity-Modulated | 3 | 2013 | 806 | 0.390 |
Why?
|
| Carcinoma, Lobular | 2 | 2015 | 484 | 0.390 |
Why?
|
| Receptors, Estrogen | 8 | 2012 | 2186 | 0.390 |
Why?
|
| Chemotherapy, Adjuvant | 12 | 2015 | 3471 | 0.380 |
Why?
|
| Disease-Free Survival | 9 | 2016 | 6891 | 0.370 |
Why?
|
| Combined Modality Therapy | 14 | 2016 | 8621 | 0.370 |
Why?
|
| Patient Preference | 2 | 2013 | 886 | 0.330 |
Why?
|
| Neoadjuvant Therapy | 4 | 2015 | 2721 | 0.330 |
Why?
|
| Appointments and Schedules | 1 | 2011 | 414 | 0.310 |
Why?
|
| Receptor, erbB-2 | 7 | 2012 | 2410 | 0.300 |
Why?
|
| Neoplasm Invasiveness | 8 | 2015 | 3612 | 0.300 |
Why?
|
| Societies, Medical | 6 | 2016 | 3740 | 0.290 |
Why?
|
| Lymph Node Excision | 7 | 2012 | 1248 | 0.280 |
Why?
|
| Female | 71 | 2017 | 379592 | 0.270 |
Why?
|
| Follow-Up Studies | 18 | 2017 | 39004 | 0.270 |
Why?
|
| Radiotherapy Dosage | 9 | 2011 | 2876 | 0.260 |
Why?
|
| Medical Oncology | 2 | 2014 | 2235 | 0.260 |
Why?
|
| Genetic Markers | 1 | 2011 | 2633 | 0.240 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2016 | 9941 | 0.230 |
Why?
|
| Age Factors | 10 | 2016 | 18355 | 0.220 |
Why?
|
| Lymphedema | 2 | 2016 | 528 | 0.220 |
Why?
|
| Humans | 75 | 2017 | 742088 | 0.200 |
Why?
|
| Prognosis | 12 | 2017 | 29010 | 0.200 |
Why?
|
| Postoperative Period | 2 | 2016 | 1839 | 0.190 |
Why?
|
| Mammography | 4 | 2008 | 2474 | 0.190 |
Why?
|
| Sentinel Lymph Node Biopsy | 5 | 2011 | 701 | 0.190 |
Why?
|
| Middle Aged | 34 | 2017 | 213127 | 0.180 |
Why?
|
| Neoplasms, Second Primary | 3 | 2014 | 1052 | 0.180 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2013 | 876 | 0.180 |
Why?
|
| Axilla | 4 | 2012 | 588 | 0.170 |
Why?
|
| Lymphatic Irradiation | 2 | 2010 | 104 | 0.170 |
Why?
|
| Aged, 80 and over | 13 | 2016 | 57683 | 0.160 |
Why?
|
| Radiation Dosage | 5 | 2014 | 1927 | 0.160 |
Why?
|
| Research | 2 | 2012 | 1999 | 0.160 |
Why?
|
| Genetic Testing | 1 | 2011 | 3439 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 5 | 2016 | 7276 | 0.150 |
Why?
|
| Time Factors | 8 | 2016 | 40054 | 0.150 |
Why?
|
| Treatment Outcome | 15 | 2014 | 62966 | 0.140 |
Why?
|
| Patient Satisfaction | 1 | 2009 | 3391 | 0.140 |
Why?
|
| Radiotherapy | 3 | 2014 | 1525 | 0.140 |
Why?
|
| Aged | 24 | 2016 | 162944 | 0.140 |
Why?
|
| Survival Rate | 7 | 2012 | 12773 | 0.140 |
Why?
|
| Adult | 27 | 2016 | 213712 | 0.140 |
Why?
|
| Reoperation | 4 | 2017 | 4200 | 0.130 |
Why?
|
| Advisory Committees | 2 | 2009 | 773 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2015 | 6534 | 0.130 |
Why?
|
| Risk Factors | 9 | 2017 | 72145 | 0.120 |
Why?
|
| Analysis of Variance | 4 | 2011 | 6365 | 0.110 |
Why?
|
| Career Choice | 2 | 2012 | 743 | 0.110 |
Why?
|
| United States | 17 | 2016 | 69693 | 0.110 |
Why?
|
| Retreatment | 1 | 2015 | 604 | 0.110 |
Why?
|
| Breast Neoplasms, Male | 1 | 2014 | 210 | 0.110 |
Why?
|
| Informed Consent | 2 | 2009 | 991 | 0.110 |
Why?
|
| Retrospective Studies | 14 | 2016 | 77098 | 0.100 |
Why?
|
| Prospective Studies | 8 | 2016 | 53187 | 0.100 |
Why?
|
| Tumor Burden | 2 | 2015 | 1905 | 0.100 |
Why?
|
| Evaluation Studies as Topic | 1 | 2013 | 1676 | 0.100 |
Why?
|
| Evidence-Based Medicine | 2 | 2016 | 3611 | 0.090 |
Why?
|
| Cyclophosphamide | 3 | 2005 | 2236 | 0.090 |
Why?
|
| Specialty Boards | 1 | 2012 | 227 | 0.090 |
Why?
|
| Fluorouracil | 2 | 2005 | 1615 | 0.090 |
Why?
|
| Survival Analysis | 3 | 2013 | 10248 | 0.090 |
Why?
|
| Radiation Pneumonitis | 2 | 2006 | 104 | 0.080 |
Why?
|
| Cohort Studies | 5 | 2017 | 40450 | 0.080 |
Why?
|
| Internship and Residency | 2 | 2007 | 5774 | 0.080 |
Why?
|
| Methotrexate | 2 | 2005 | 1720 | 0.080 |
Why?
|
| Estrogen Antagonists | 1 | 2008 | 151 | 0.080 |
Why?
|
| Tamoxifen | 2 | 2009 | 980 | 0.080 |
Why?
|
| History, 21st Century | 1 | 2014 | 1533 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2011 | 11472 | 0.080 |
Why?
|
| Breast | 1 | 2016 | 1958 | 0.070 |
Why?
|
| Neoplasm Metastasis | 2 | 2008 | 4839 | 0.070 |
Why?
|
| SEER Program | 3 | 2011 | 1507 | 0.070 |
Why?
|
| Career Mobility | 2 | 2007 | 262 | 0.070 |
Why?
|
| Heart Diseases | 2 | 2014 | 2789 | 0.070 |
Why?
|
| History, 20th Century | 1 | 2014 | 2739 | 0.070 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2006 | 505 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2013 | 12344 | 0.060 |
Why?
|
| Neoplasms | 1 | 2014 | 21596 | 0.060 |
Why?
|
| Poisson Distribution | 1 | 2006 | 512 | 0.060 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2011 | 1622 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2011 | 15056 | 0.060 |
Why?
|
| Mammaplasty | 3 | 2010 | 1195 | 0.060 |
Why?
|
| Clinical Trials as Topic | 4 | 2011 | 7901 | 0.060 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2005 | 358 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2009 | 35342 | 0.060 |
Why?
|
| African Americans | 1 | 2002 | 23 | 0.060 |
Why?
|
| Research Subjects | 1 | 2005 | 238 | 0.050 |
Why?
|
| Antineoplastic Protocols | 1 | 2002 | 47 | 0.050 |
Why?
|
| Doxorubicin | 2 | 2005 | 2215 | 0.050 |
Why?
|
| Inhalation | 1 | 2002 | 143 | 0.050 |
Why?
|
| BRCA2 Protein | 1 | 2006 | 790 | 0.050 |
Why?
|
| Antineoplastic Agents | 4 | 2014 | 13655 | 0.050 |
Why?
|
| Guideline Adherence | 1 | 2011 | 2266 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2009 | 1509 | 0.050 |
Why?
|
| Risk | 2 | 2011 | 9679 | 0.050 |
Why?
|
| DNA, Neoplasm | 1 | 2006 | 1758 | 0.050 |
Why?
|
| Observer Variation | 1 | 2007 | 2593 | 0.050 |
Why?
|
| Young Adult | 3 | 2016 | 56350 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2009 | 2245 | 0.050 |
Why?
|
| Italy | 1 | 2002 | 828 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2002 | 15244 | 0.040 |
Why?
|
| Mesothelioma | 1 | 2006 | 818 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 2006 | 1145 | 0.040 |
Why?
|
| Teaching | 1 | 2007 | 1174 | 0.040 |
Why?
|
| Disclosure | 1 | 2005 | 736 | 0.040 |
Why?
|
| Incidence | 5 | 2014 | 20928 | 0.040 |
Why?
|
| Faculty, Medical | 1 | 2007 | 1182 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2006 | 1786 | 0.040 |
Why?
|
| Educational Measurement | 1 | 2005 | 1206 | 0.040 |
Why?
|
| Survivors | 2 | 2014 | 2286 | 0.040 |
Why?
|
| Salvage Therapy | 1 | 2005 | 1269 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2005 | 1707 | 0.040 |
Why?
|
| Radiology | 1 | 2012 | 2090 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2011 | 3203 | 0.040 |
Why?
|
| Disease Progression | 1 | 2014 | 13256 | 0.040 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2016 | 170 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 8425 | 0.030 |
Why?
|
| Radiation Injuries | 1 | 2002 | 1178 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2005 | 2283 | 0.030 |
Why?
|
| Research Design | 1 | 2008 | 5979 | 0.030 |
Why?
|
| Curriculum | 1 | 2005 | 3589 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2013 | 23320 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2012 | 8829 | 0.020 |
Why?
|
| Drug Administration Schedule | 2 | 2011 | 4929 | 0.020 |
Why?
|
| Radiography | 1 | 2002 | 7010 | 0.020 |
Why?
|
| Sarcoma | 1 | 2002 | 1895 | 0.020 |
Why?
|
| Logistic Models | 3 | 2011 | 13403 | 0.020 |
Why?
|
| Utilization Review | 1 | 2011 | 392 | 0.020 |
Why?
|
| Authorship | 1 | 2012 | 271 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2012 | 1799 | 0.020 |
Why?
|
| Mastectomy, Extended Radical | 1 | 2008 | 3 | 0.020 |
Why?
|
| Faculty | 1 | 2012 | 383 | 0.020 |
Why?
|
| Carcinoma in Situ | 1 | 2014 | 802 | 0.020 |
Why?
|
| Mastectomy, Modified Radical | 1 | 2008 | 62 | 0.020 |
Why?
|
| Preoperative Period | 1 | 2010 | 546 | 0.020 |
Why?
|
| Research Support as Topic | 1 | 2012 | 704 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2011 | 12242 | 0.020 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2008 | 281 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2004 | 6347 | 0.020 |
Why?
|
| Employment | 1 | 2012 | 1124 | 0.020 |
Why?
|
| Reimbursement Mechanisms | 1 | 2011 | 670 | 0.020 |
Why?
|
| Guanine | 1 | 2006 | 274 | 0.020 |
Why?
|
| Ovarian Neoplasms | 1 | 2002 | 4823 | 0.020 |
Why?
|
| Glutamates | 1 | 2006 | 398 | 0.020 |
Why?
|
| Patient Care Planning | 1 | 2010 | 921 | 0.020 |
Why?
|
| Breast Diseases | 1 | 2007 | 443 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2008 | 2027 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2007 | 20086 | 0.010 |
Why?
|
| Carcinoma, Medullary | 1 | 2004 | 123 | 0.010 |
Why?
|
| Program Evaluation | 1 | 2012 | 2485 | 0.010 |
Why?
|
| Melanoma | 1 | 2002 | 5462 | 0.010 |
Why?
|
| Congresses as Topic | 1 | 2008 | 764 | 0.010 |
Why?
|
| Medicare | 2 | 2011 | 6532 | 0.010 |
Why?
|
| Forecasting | 1 | 2011 | 2948 | 0.010 |
Why?
|
| Genes, BRCA1 | 1 | 2006 | 780 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2002 | 6754 | 0.010 |
Why?
|
| Mentors | 1 | 2007 | 630 | 0.010 |
Why?
|
| Animals | 1 | 2014 | 168561 | 0.010 |
Why?
|
| Cardiac Volume | 1 | 2002 | 210 | 0.010 |
Why?
|
| Diaphragm | 1 | 2002 | 347 | 0.010 |
Why?
|
| Cisplatin | 1 | 2006 | 1637 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2006 | 2615 | 0.010 |
Why?
|
| Biopsy | 1 | 2011 | 6756 | 0.010 |
Why?
|
| Pneumonectomy | 1 | 2006 | 1093 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 3691 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2011 | 9846 | 0.010 |
Why?
|
| Calcinosis | 1 | 2007 | 1497 | 0.010 |
Why?
|
| Respiratory Insufficiency | 1 | 2006 | 1199 | 0.010 |
Why?
|
| Smoking | 1 | 2014 | 8969 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2002 | 13019 | 0.010 |
Why?
|
| Educational Status | 1 | 2005 | 2533 | 0.010 |
Why?
|
| Attitude to Health | 1 | 2005 | 2051 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2005 | 5062 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2010 | 7716 | 0.010 |
Why?
|
| Quality of Health Care | 1 | 2010 | 4369 | 0.010 |
Why?
|
| Women's Health | 1 | 2002 | 2034 | 0.010 |
Why?
|
| Male | 4 | 2014 | 349538 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2007 | 9274 | 0.010 |
Why?
|
| Prevalence | 1 | 2006 | 15194 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2002 | 7770 | 0.010 |
Why?
|
| Heart | 1 | 2002 | 4462 | 0.000 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 15108 | 0.000 |
Why?
|
Concepts
(200)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(47)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_